National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

renal cell carcinoma peptides vaccine IMA901
A multipeptide cancer vaccine targeting renal cell carcinoma with potential immunopotentiating activity. Renal cell carcinoma peptides vaccine IMA901 consists of 10 different synthetic tumor-associated peptide (TUMAP) antigens (9 HLA-class I-binding and 1 HLA class II-binding); endogenously, these TUMAPs are expressed by the majority of renal cell carcinomas. Vaccination with this agent may significantly increase host cytotoxic T-lymphocyte (CTL) immune responses against tumor cells expressing these peptide antigens. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Code name:IMA901



Previous:Remeron, Remicade, Remifemin, remifentanil hydrochloride, Remitogen
Next:renal cell carcinoma/CD40L RNA-transfected autologous dendritic cell vaccine AGS-003, Rencarex, Renova, Resectisol, Respbid

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov